We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

ADVANCED INSTRUMENTS

Advanced Instruments designs, manufactures and markets laboratory products for the clinical, food and dairy, microbio... read more Featured Products: More products

Download Mobile App




Automated Cerebrospinal Fluid Cell Counter Granted USA Diagnostics Marketing Approval

By LabMedica International staff writers
Posted on 18 Jul 2016
The [U.S.] Food and Drug Administration has granted diagnostic use marketing approval (510(k) clearance) for an automated cell counting system that accurately quantifies the low number of cells found in cerebrospinal fluid (CSF).

The Advanced Instruments, Inc., (Norwood, MA, USA) patented GloCyte Automated Cell Counter System delivers highly accurate and precise total nucleated cell (TNC) and red blood cell (RBC) results using a novel combination of fluorescence technology, highly specific reagents, and an intelligent counting algorithm. More...
It provides accurate cell counts at clinically relevant low levels and reduces valuable time spent counting those more difficult specimens.

Analyses preformed with the GloCyteSystem require only 30 microliters of sample per test. The instrument uses disposable test cartridges ensuring no sample carryover and easy disposal, and it includes built-in quality control.

The GloCyte instrument, which should be available in the USA from September 2016, is complemented by the 510(k) approved GloCyte Low and High Level Controls.

“To date, there has not been a way to provide dependable low cell counts,” said John Coughlin, president and CEO of Advanced Instruments. “We use a novel combination of fluorescence, microscopy with digital image analysis principles, highly specific reagents, and an intelligent counting algorithm to provide accurate and precise cell counts. We are very excited as this marks a major achievement in giving laboratories a new way to obtain reliable and timely CSF results.”

Related Links:
Advanced Instruments



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.